Pyridine analogues of nimesulide: design, synthesis, and in vitro and in vivo pharmacological evaluation as promising cyclooxygenase 1 and 2 inhibitors
Renard, Jean-François ; Université de Liège - ULiège > Département de pharmacie > Chimie pharmaceutique
Arslan, Deniz ; Université de Liège - ULiège > Département de pharmacie > Chimie pharmaceutique
Garbacki, Nancy ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Laboratoire des tissus conjonctifs
Pirotte, Bernard ; Université de Liège - ULiège > Département de pharmacie > Chimie pharmaceutique
de Leval, Xavier
Language :
English
Title :
Pyridine analogues of nimesulide: design, synthesis, and in vitro and in vivo pharmacological evaluation as promising cyclooxygenase 1 and 2 inhibitors
Publication date :
2009
Journal title :
Journal of Medicinal Chemistry
ISSN :
0022-2623
eISSN :
1520-4804
Publisher :
American Chemical Society, Washington, United States - District of Columbia
Vane, J. R. Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-Like Drugs. Nat. New Biol. 1971, 231, 232-235.
Abnet, C. C.; Freedman, N. D.; Kamangar, F.; Leitzmann, M. F.; Hollenbeck, A. R.; Schatzkin, A. Nonsteroidal Anti-inflammatory Drugs and Risk of Gastric and Oesophageal Adenocarcinomas: Results from a Cohort Study and a Meta-Analysis. Br. J. Cancer 2009, 100, 551-557.
Dassesse, T.; de Leval, X.; de Leval, L.; Pirotte, B.; Castronovo, V.; Waltregny, D. Activation of the Thromboxane A2 Pathway in Human Prostate Cancer Correlates with Tumor Gleason Score and Pathologic Stage. Eur. Urol. 2006, 50, 1021-1031.
Hernandez-Diaz, S.; Garcia Rodriguez, L. A. Nonsteroidal Antiinflammatory Drugs and Risk of Lung Cancer. Int. J. Cancer 2007, 120, 1565-1572. (Pubitemid 46355395)
Iwama, T. NSAIDs and Colorectal Cancer Prevention. J. Gastroenterol. 2009, 44 (Suppl. 19), 72-76.
Jacobs, E. J.; Thun, M. J.; Bain, E. B.; Rodriguez, C.; Henley, S. J.; Calle, E. E. A Large Cohort Study of Long-Term Daily Use of Adult-Strength Aspirin and Cancer Incidence. J. Natl. Cancer Inst. 2007, 99, 608-615.
Takkouche, B.; Regueira-Mendez, C.; Etminan, M. Breast Cancer and Use of Nonsteroidal Anti-inflammatory Drugs: A Meta- Analysis. J. Natl. Cancer Inst. 2008, 100, 1439-1447.
Weggen, S.; Rogers, M.; Eriksen, J. NSAIDs: Small Molecules for Prevention of Alzheimer's Disease or Precursors for Future Drug Development? Trends Pharmacol. Sci. 2007, 28, 536-543.
Aisen, P. S.; Schafer, K. A.; Grundman, M.; Pfeiffer, E.; Sano, M.; Davis, K. L.; Farlow, M. R.; Jin, S.; Thomas, R. G.; Thal, L. J. Effects of Rofecoxib or Naproxen vs Placebo on Alzheimer Disease Progression: A Randomized Controlled Trial. JAMA, J. Am. Med. Assoc. 2003, 289, 2819-2826.
Esposito, E.; Di Matteo, V.; Benigno, A.; Pierucci, M.; Crescimanno, G.; Di Giovanni, G. Nonsteroidal Anti-inflammatory Drugs in Parkinson's Disease. Exp. Neurol. 2007, 205, 295-312.
Hoffmann, C. Cox-2 in Brain and Spinal Cord Implications for Therapeutic Use. Curr. Med. Chem. 2000, 7, 1113-1120.
Cryer, B. Mucosal Defense and Repair. Role of Prostaglandins in the Stomach and Duodenum. Gastroenterol. Clin. North Am. 2001, 30, 877-894, v-vi.
Wallace, J. L. Pathogenesis of NSAID-Induced Gastroduodenal Mucosal Injury. Best Pract. Res. Clin. Gastroenterol. 2001, 15, 691-703.
Whelton, A. Nephrotoxicity of Nonsteroidal Anti-inflammatory Drugs: Physiologic Foundations and Clinical Implications. Am. J. Med. 1999, 106, 13S-24S.
Prasit, P.; Wang, Z.; Brideau, C.; Chan, C. C.; Charleson, S.; Cromlish, W.; Ethier, D.; Evans, J. F.; Ford-Hutchinson, A. W.; Gauthier, J. Y.; Gordon, R.; Guay, J.; Gresser, M.; Kargman, S.; Kennedy, B.; Leblanc, Y.; Leger, S.; Mancini, J.; O'Neill, G. P.; Ouellet, M.; Percival, M. D.; Perrier, H.; Riendeau, D.; Rodger, I.; Zamboni, R.; et al. The Discovery of Rofecoxib, [Mk 966, Vioxx, 4-(40-Methylsulfonylphenyl)-3-phenyl-2(5h)-furanone], an Orally Active Cyclooxygenase-2-Inhibitor. Bioorg. Med. Chem. Lett. 1999, 9, 1773-1778.
Penning, T. D.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W.; Docter, S.; Graneto, M. J.; Lee, L. F.; Malecha, J. W.; Miyashiro, J. M.; Rogers, R. S.; Rogier, D. J.; Yu, S. S.; Anderson, G. D.; Burton, E. G.; Cogburn, J. N.; Gregory, S. A.; Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.; Zhang, Y. Y.; Isakson, P. C. Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol- 1-Yl]benzenesulfonamide (Sc-58635, Celecoxib). J. Med. Chem. 1997, 40, 1347-1365.
Sorbera, L. A.; Castãner, R. M.; Silvestre, J.; Castañer, J. Etoricoxib. Analgesic Drug, Antiarthritic, Cyclooxygenase-2 Inhibitor. Drugs Future 2001, 26, 346-353.
Talley, J. J.; Brown, D. L.; Carter, J. S.; Graneto, M. J.; Koboldt, C. M.; Masferrer, J. L.; Perkins, W. E.; Rogers, R. S.; Shaffer, A. F.; Zhang, Y. Y.; Zweifel, B. S.; Seibert, K. 4-[5-Methyl-3- phenylisoxazol-4-yl]- benzenesulfonamide, Valdecoxib: A Potent and Selective Inhibitor of Cox-2. J. Med. Chem. 2000, 43, 775-777.
Rostom, A.; Muir, K.; Dube, C.; Jolicoeur, E.; Boucher, M.; Joyce, J.; Tugwell, P.; Wells, G. W. Gastrointestinal Safety of Cyclooxygenase- 2 Inhibitors: A Cochrane Collaboration Systematic Review. Clin. Gastroenterol. Hepatol. 2007, 5, 818-828.
Bombardier, C.; Laine, L.; Reicin, A.; Shapiro, D.; Burgos-Vargas, R.; Davis, B.; Day, R.; Ferraz, M. B.; Hawkey, C. J.; Hochberg, M. C.; Kvien, T. K.; Schnitzer, T. J. Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis. Vigor Study Group. N. Engl. J. Med. 2000, 343, 1520-1528.
Bresalier, R. S.; Sandler, R. S.; Quan, H.; Bolognese, J. A.; Oxenius, B.; Horgan, K.; Lines, C.; Riddell, R.; Morton, D.; Lanas, A.; Konstam, M. A.; Baron, J. A. Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial. N. Engl. J. Med. 2005, 352, 1092-1102.
Dogne, J. M.; Hanson, J.; Supuran, C.; Pratico, D. Coxibs and Cardiovascular Side-Effects: From Light to Shadow. Curr. Pharm. Des 2006, 12, 971-975.
de Leval, X.; Hanson, J.; David, J. L.; Masereel, B.; Pirotte, B.; Dogne, J. M. New Developments on Thromboxane and Prostacyclin Modulators Part II: Prostacyclin Modulators. Curr. Med. Chem. 2004, 11, 1243-1252.
Dogne, J. M.; de Leval, X.; Hanson, J.; Frederich, M.; Lambermont, B.; Ghuysen, A.; Casini, A.; Masereel, B.; Ruan, K. H.; Pirotte, B.; Kolh, P. New Developments on Thromboxane and Prostacyclin Modulators Part I: Thromboxane Modulators. Curr. Med. Chem. 2004, 11, 1223-1241.
Di Fiore, A.; Pedone, C.; D'Ambrosio, K.; Scozzafava, A.; De Simone, G.; Supuran, C. T. Carbonic Anhydrase Inhibitors: Valdecoxib Binds to a Different Active Site Region of the Human Isoform II as Compared to the Structurally Related Cyclooxygenase II "Selective" Inhibitor Celecoxib. Bioorg. Med. Chem. Lett. 2006, 16, 437-442.
Weber, A.; Casini, A.; Heine, A.; Kuhn, D.; Supuran, C. T.; Scozzafava, A.; Klebe, G. Unexpected Nanomolar Inhibition of Carbonic Anhydrase by Cox-2-Selective Celecoxib: New Pharmacological Opportunities Due to Related Binding Site Recognition. J. Med. Chem. 2004, 47, 550-557.
Mason, R. P.; Walter, M. F.; Day, C. A.; Jacob, R. F. A Biological Rationale for the Cardiotoxic Effects of Rofecoxib: Comparative Analysis with Other Cox-2 Selective Agents and NSAIDs. Subcell. Biochem. 2007, 42, 175-190.
Mason, R. P.; Walter, M. F.; McNulty, H. P.; Lockwood, S. F.; Byun, J.; Day, C. A.; Jacob, R. F. Rofecoxib Increases Susceptibility of Human LdL and Membrane Lipids to Oxidative Damage: A Mechanism of Cardiotoxicity. J. Cardiovasc. Pharmacol. 2006, 47 (Suppl. 1), S7-S14.
Walter, M. F.; Jacob, R. F.; Day, C. A.; Dahlborg, R.; Weng, Y.; Mason, R. P. Sulfone Cox-2 Inhibitors Increase Susceptibility of Human LdL and Plasma to Oxidative Modification: Comparison to Sulfonamide Cox-2 Inhibitors and NSAIDs. Atherosclerosis 2004, 177, 235-243.
Swingle, K. F.; Moore, G. G.; Grant, T. J. 4-Nitro-2- Phenoxymethanesulfonanilide (R-805): A Chemically Novel Anti-inflammatory Agent. Arch. Int. Pharmacodyn. Ther. 1976, 221, 132-139.
Cullen, L.; Kelly, L.; Connor, S. O.; Fitzgerald, D. J. Selective Cyclooxygenase-2 Inhibition by Nimesulide in Man. J. Pharmacol. Exp. Ther. 1998, 287, 578-582.
Julemont, F.; de Leval, X.; Michaux, C.; Damas, J.; Charlier, C.; Durant, F.; Pirotte, B.; Dogne, J. M. Spectral and Crystallographic Study of Pyridinic Analogues of Nimesulide: Determination of the Active Form of Methanesulfonamides as Cox-2 Selective Inhibitors. J. Med. Chem. 2002, 45, 5182-5185.
Julemont, F.; de Leval, X.; Michaux, C.; Renard, J. F.; Winum, J. Y.; Montero, J. L.; Damas, J.; Dogne, J. M.; Pirotte, B. Design, Synthesis, and Pharmacological Evaluation of Pyridinic Analogues of Nimesulide as Cyclooxygenase-2 Selective Inhibitors. J. Med. Chem. 2004, 47, 6749-6759.
Ochiai, E. Recent Japanese Work on the Chemistry of Pyridine 1-Oxide and Related Compounds. J. Org. Chem. 1953, 18, 534-551.
de Leval, X.; Delarge, J.; Devel, P.; Neven, P.; Michaux, C.; Masereel, B.; Pirotte, B.; David, J. L.; Henrotin, Y.; Dogne, J. M. Evaluation of Classical NSAIDs and Cox-2 Selective Inhibitors on Purified Ovine Enzymes and Human Whole Blood. Prostaglandins Leukotrienes Essent. Fatty Acids 2001, 64, 211-216.
Garbacki, N.; Tits, M.; Angenot, L.; Damas, J. Inhibitory Effects of Proanthocyanidins from Ribes nigrum Leaves on Carrageenin Acute Inflammatory Reactions Induced in Rats. BMC Pharmacol. 2004, 4, 25. (Pubitemid 40177089)
Futaki, N.; Yoshikawa, K.; Hamasaka, Y.; Arai, I.; Higuchi, S.; Iizuka, H.; Otomo, S. Ns-398, a Novel Nonsteroidal Anti-inflammatory Drug with Potent Analgesic and Antipyretic Effects, Which Causes Minimal Stomach Lesions. Gen. Pharmacol. 1993, 24, 105-110.
Patrignani, P.; Panara, M. R.; Sciulli, M. G.; Santini, G.; Renda, G.; Patrono, C. Differential Inhibition of Human Prostaglandin Endoperoxide Synthase-1 and -2 by Nonsteroidal Anti-inflammatory Drugs. J. Physiol. Pharmacol. 1997, 48, 623-631.
Young, J. M.; Panah, S.; Satchawatcharaphong, C.; Cheung, P. S. Human Whole Blood Assays for Inhibition of Prostaglandin G/H Synthases-1 and -2 Using A23187 and Lipopolysaccharide Stimulation of Thromboxane B2 Production. Inflamm. Res. 1996, 45, 246-253.
Li, F.; Chordia, M. D.; Huang, T.; Macdonald, T. L. In Vitro Nimesulide Studies toward Understanding Idiosyncratic Hepatotoxicity: Diiminoquinone Formation and Conjugation. Chem. Res. Toxicol. 2009, 22, 72-80.
